(NASDAQ: BNTC) Benitec Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 90.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.86%.
Benitec Biopharma's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast BNTC's revenue for 2028 to be $408,457,298, with the lowest BNTC revenue forecast at $123,902,214, and the highest BNTC revenue forecast at $693,012,382. On average, 2 Wall Street analysts forecast BNTC's revenue for 2029 to be $1,985,454,223, with the lowest BNTC revenue forecast at $1,607,578,722, and the highest BNTC revenue forecast at $2,363,329,724.
In 2030, BNTC is forecast to generate $6,472,840,646 in revenue, with the lowest revenue forecast at $3,104,117,959 and the highest revenue forecast at $9,841,563,333.